Logo Tafalgie Therapeutics

Project chronology & history

There were a number of key stages in this project, extending from research to development :

1939:
Discovery of the type C low-threshold mechanoreceptor neuron class (C-LTMR) by Yngve Zotterman
2007:
Identification of the TAFA4 protein as a specific molecular marker of C-LTMR sensory neurons
2010:
Elucidation, by the team of Aziz Moqrich, of the role of the TAFA4 protein in pain gate control
2013:
Filing of a first patent linked to TAFA4 by Aziz Moqrich
2021/2022:
Filing of two new product patents in December 2021 and May 2022 (for polypeptide derived from TAFA4) by Tafalgie Therapeutics and the CNRS

Others key stages

2005-2006

Creation of 'Chronic Pain'

Creation of the team 'Chronic Pain' :

Molecular and cellular mechanisms” team by Dr. Aziz Moqrich from the IBDM, and Dr. Stephane Gaillard, who joined this new team

2020

Sublicense exploitation agreement

Sub-licence exploitation agreement

with Satt Sud-Est (SEE)
What is the SATT SUD-EST ?

2019-2020

Creation of Tafalgie Therapeutics

Creation of the company :

Completion of the Tafalgie Therapeutics founders by the arrival of Laurent Labatut and the establishment of a support team

2022

The company begins operating, with the performance of preclinical studies...

The company begins operating, with the performance of preclinical studies

R&D activities, regulatory activities, the establishment of a scientific advisory board and efforts to obtain financial support

Contact us
for more information

JOIN US

Follow us to keep up with our news